Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo
By M. Chen, M. Pittet, L. Gorelik, R. Flavell, Ralph Weissleder, H. von Boehmer, K. Khazaie. 2005
775 citations recorded by the source corpus.
Cancer patients can harbor significant numbers of CD8 and CD4 T cells with specificities to tumor antigens (Ags). Yet, in most cases, such T cells fail to eradicate the tumor in vivo. Here, we investigated the interference of Ag-specific CD4+CD25+ regulatory T cells (Treg) with the tumor-specific CD8 T cell immune response in vivo, by monitoring the homing, expansion, and effector function of both subsets in draining and nondraining lymph nodes. The results show that CD8 cells expand to the same extent and produce similar levels of IFN-γ in the presence or absence of Ag-specific Treg. Nevertheless, these Treg abrogate CD8 T cell-mediated tumor rejection by specifically suppressing the cytotoxicity of expanded CD8 cells. The molecular mechanism of suppression involves TGF-β because expression of a dominant-negative TGF-β receptor by tumor-specific CD8 cells renders them resistant to suppression and is associated with tumor rejection and unimpaired cytotoxicity.
Subfields: Conservation, History, Literature and Literary Theory
View Paper: https://www.semanticscholar.org/paper/29c0e621bfab4424b93ffb0181a07804fa3ece12
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Mechanisms of foxp3+ T regulatory cell-mediated suppression. (2009, result): “In contrast to the effects of antigen-specific Treg cells on CD4+ effector T cells, Chen et al. (2005) have shown that antigenspecific Treg cells do not inhibit the expansion of CD8+ effector cells or their differentiation to cytotoxic T lymphocytes (CTLs), but do block the ability of the activated…”
- Transforming Grown Factor-β Signaling in Immunity and Cancer (2019, positive): “In addition to inducing a T regulatory program, TGF-β is utilized by Tregs to suppress antitumor immune responses (Chen et al., 2005; Mempel et al., 2006).”
- A cytokine-mediated link between innate immunity, inflammation, and cancer. (2007, positive): “In addition, both TGF-β –induced changes in the microenvironment, to favor angiogenesis, and inhibition of tumor-specific CD8 + T cells promote tumor development (Figure 3) (117, 125).”
- Mechanisms of immune evasion by tumors. (2006, background): “Recent experiments by Chen et al. (2005) rather convincingly demonstrated a role for TGF‐b in Treg mediated suppression of CD8 Tcell antitumor responses.”